Cost-Effectiveness Analysis of Smoking Cessation Interventions With Behavioral Support: A Study Based on the Benefits of Smoking Cessation on Outcomes (BENESCO) Model

被引:1
作者
Park, Sun-Kyeong [1 ]
Kang, Dong-Won [2 ]
Lee, Eui-Kyung [2 ]
机构
[1] Catholic Univ Korea, Coll Pharm, Bucheon, Gyeonggi Do, South Korea
[2] Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi Do, South Korea
关键词
NICOTINE-REPLACEMENT THERAPY; SUSTAINED-RELEASE BUPROPION; VARENICLINE; SERVICES; PROGRAM; UTILITY; SMOKERS; HEALTH; TRIAL; KOREA;
D O I
10.1093/ntr/ntac172
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction Few studies have compared cost-effectiveness of different smoking cessation interventions (SCIs) that include behavioral support, considering smoking-related diseases. Therefore, we compare the cost-effectiveness of SCIs with behavioral support in South Korea using the Benefits of Smoking Cessation on Outcomes (BENESCO) model. Aims and Methods We used the BENESCO model to estimate the cost and utility of the SCIs with behavioral support, including pharmacist counseling with nicotine replacement therapy (pharmacist+NRT), expert counseling with NRT (expert+NRT), and expert counseling with varenicline (expert+varenicline). The target population was adult smokers who wanted to cease smoking within 1 month. We applied transitional probabilities and epidemiological data from the literature. Medical costs and utilities were calculated using claims and national survey data, respectively. Cost-effectiveness was evaluated within the threshold (17 926 USD per quality-adjusted life years [QALYs]) by incremental cost-effectiveness ratio (ICER). Results The model cohort included 1 219 390 male and 298 511 female smokers. The pharmacist+NRT group had 32 842 more QALYs gained and 26 689 958 USD less expended than the expert+NRT group. The ICER for the expert+varenicline group versus the pharmacist+NRT and expert+NRT groups was 27 247 and 4074 USD per QALY, respectively. The robustness of the results was confirmed by sensitivity analyses, except for the discount rate and cost of the expert+varenicline group. Conclusions In Korea, pharmacist counseling with NRT showed higher QALY gains and lower costs than expert counseling with NRT. Expert counseling with varenicline was more effective for smoking cessation and more cost-effective than expert counseling with NRT but was not cost-effective compared with pharmacist counseling with NRT. Implications This study provides evidence for decision-making on smoking cessation programs by evaluating the cost-effectiveness of SCIs. Furthermore, we attempted to use the BENESCO model to compare and evaluate the cost-effectiveness of SCIs with behavioral support. It is meaningful because this study showed the availability of using the BENESCO model in the future cost-effectiveness analysis of various SCIs.
引用
收藏
页码:2011 / 2017
页数:7
相关论文
共 50 条
  • [11] Cost-effectiveness of face-to-face smoking cessation interventions:: A dynamic modeling study
    Feenstra, TL
    Hamberg-van Reenen, HH
    Hoogenveen, RT
    Rutten-van Mölken, MPMH
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 178 - 190
  • [12] Cost-Effectiveness of Pharmacological Smoking Cessation Therapies A Systematic Literature Review
    Aumann, I.
    Rozanski, K.
    Damm, K.
    von der Schulenburg, J. -M. Graf
    [J]. GESUNDHEITSWESEN, 2016, 78 (10) : 660 - 671
  • [13] Cost-effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD
    Huber, Manuel B.
    Praeger, Maximilian
    Coyle, Kathryn
    Coyle, Doug
    Lester-George, Adam
    Trapero-Bertran, Marta
    Nemeth, Bertalan
    Cheung, Kei Long
    Stark, Renee
    Vogl, Matthias
    Pokhrel, Subhash
    Leidl, Reiner
    [J]. ADDICTION, 2018, 113 : 52 - 64
  • [14] Cost Effectiveness of Smoking Cessation
    Seo, H. G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1690 - S1691
  • [15] Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD
    Hoogendoorn, Martine
    Feenstra, Talitha L.
    Hoogenveen, Rudolf T.
    Rutten-van Molken, Maureen P. M. H.
    [J]. THORAX, 2010, 65 (08) : 711 - 718
  • [16] The Cost-Effectiveness of an Extended Course (12+12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States: An Extension and Update to the BENESCO Model
    Knight, Chris
    Howard, Paul
    Baker, Christine L.
    Marton, Jeno P.
    [J]. VALUE IN HEALTH, 2010, 13 (02) : 209 - 214
  • [17] Cost-effectiveness of an Intensive Smoking Cessation Intervention for COPD Outpatients
    Christenhusz, Lieke C. A.
    Prenger, Rilana
    Pieterse, Marcel E.
    Seydel, Erwin R.
    van der Palen, Job
    [J]. NICOTINE & TOBACCO RESEARCH, 2012, 14 (06) : 657 - 663
  • [18] Long-Term Cost-Effectiveness of Smoking Cessation Interventions in People With Mental Disorders: A Dynamic Decision Analytical Model
    Wu, Qi
    Gilbody, Simon
    Li, Jinshuo
    Wang, Han-, I
    Parrott, Steve
    [J]. VALUE IN HEALTH, 2021, 24 (09) : 1263 - 1272
  • [19] Projected Cost-effectiveness of Smoking Cessation Interventions in Patients Hospitalized With Myocardial Infarction
    Ladapo, Joseph A.
    Jaffer, Farouc A.
    Weinstein, Milton C.
    Froelicher, Erika Sivarajan
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (01) : 39 - 45
  • [20] Cost-Effectiveness of Four Financial Incentive Programs for Smoking Cessation
    Russell, Louise B.
    Volpp, Kevin G.
    Kwong, Pui L.
    Cosgriff, Benjamin S.
    Harhay, Michael O.
    Zhu, Jingsan
    Halpern, Scott D.
    [J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (12) : 1997 - 2006